Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

Next Previous
Trial Profile

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CER-1236 (Primary) ; Cyclophosphamide; Fludarabine; Mesna
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms CertainT-1
  • Sponsors CERo Therapeutics

Most Recent Events

  • 31 Aug 2026 According to CERo Therapeutics media release, CERo has initiated the third planned cohort of the CERTAIN-T study, which is expected to evaluate the planned one billion cells/patient protocol and is currently screening patients for enrollment. The cohort is also expected to include patients with myelodysplastic syndromes (MDS) and myelofibrosis.
  • 30 Apr 2025 Status changed from not yet recruiting to recruiting.
  • 06 Mar 2025 According to CERo Therapeutics media release, company announced the execution of an agreement with contract research organization (CRO) CellCarta to manage translational assays for the upcoming Phase 1 clinical trial of CER-1236 for Acute Myeloid Leukemia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top